About Akums Drugs & Pharmaceuticals Limited

Akums Drugs & Pharmaceuticals Limited, founded in 2004, began with its first oral dosage plant in Uttarakhand and has since expanded into injectables, hormones, cosmetics/dermatology, nutraceuticals, APIs, and branded formulations. It positions itself as India’s largest CDMO, offering formulation R&D, regulatory dossiers, testing, and commercial manufacturing for domestic and global markets.

The company operates 14 facilities with 49.6 billion-unit CDMO capacity and 737.4 MT API capacity, supporting 4,146 commercialized formulations across 60 dosage forms and 21,000+ SKUs. Regulatory approvals include 998 DCGI and 997 FSSAI, alongside 100+ published patents. Akums serves 1,600+ clients, with four R&D centers and 350+ scientists. Key platforms include Akumentis (domestic branded formulations) and Maxcure Nutravedics (nutraceuticals). Akumentis ranks #58 in the Indian Pharmaceutical Market. Akums has a presence in 70+ countries across Asia, Africa, Europe, and the Americas.

 Akums Drugs & Pharmaceuticals Limited’s Business Segments

• Reportable segments: CDMO, API, Domestic Branded Formulations, International Branded Formulations, and Trade Generics.

• Portfolio: Pharmaceutical formulations across multiple therapy areas, APIs (including cephalosporins), nutraceuticals, and third-party cosmetics manufacturing. Two plants hold EU-GMP accreditation.

• Revenue by geography (FY 2024–25): 95% domestic.

• Revenue by vertical (FY 2024–25; INR million): CDMO 32,078.76; API 2,192.96; Domestic Branded Formulations 4,335.88; International Branded Formulations 1,426.13; Trade Generics 1,147.85. Total: 41,181.58.

 Akums Drugs & Pharmaceuticals Limited Key Management

• Sanjeev Jain, Managing Director.

• Sandeep Jain, Managing Director.

• Sumeet Sood, Chief Financial Officer.

Latest Updates on Akums Drugs & Pharmaceuticals Limited

• IPO: Completed in July 30–August 1, 2024 (fresh issue of 10,037,708 shares for INR 6,800 million and OFS of 17,330,435 shares for INR 11,767.37 million). Oversubscribed 63x, listed August 6, 2024, on NSE and BSE. Price band INR 646–679; listing at INR 725. Total offer size INR 18,567.37 million (INR 1,856.74 crores).

• Portfolio restructuring: Disinvested subsidiaries Amazing Research & Laboratories Ltd., May & Baker Pharmaceuticals Ltd., and Burroughs Welcome Pharmacia Pvt. Ltd. (now Hygosap Pharma) effective April 1, 2024.

• International expansion: Incorporated Akums Healthcare UK Ltd. on March 18, 2025.

• Major contract: Secured EUR 200 million CDMO contract with a leading global pharma company for European supply.

• Capacity & R&D: New injectable facility at Haridwar; expanded eye drops, bi-layered tablets, ampoules, and FFS parenterals. R&D investment INR 130 crores; 31 DCGI and 117 FSSAI approvals in FY25.

• Performance snapshot: FY 2024–25 revenue INR 4,118.20 crores; Adjusted EBITDA INR 512.73 crores; PAT INR 343.80 crores.

• Sustainability & awards: 33.70% renewable energy share, 2,100+ saplings planted, and awards including “Excellence in Pharma Contract Services – Manufacturing” and “Pharma Company of the Year” (ET RePharma Awards 2025).